TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/21/23 17:00 | 9/19/23 | RYZB | Rayzebio, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Viking Global Investors LP | CT | T | P.d | 25,000 | 18.00 | 0 | 1,389 | 392 | 1,744 | I | |||||||||||||||
9/21/23 16:59 | 9/19/23 | RYZB | Rayzebio, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Viking Global Investors LP | CT | T | P.d | 25,000 | 18.00 | 0 | 1,389 | 392 | 1,744 | I | |||||||||||||||
8/30/23 20:44 | 8/28/23 | INBX | Inhibrx, Inc. | CA | Health | BioPrd | Biological Products, (No Diag | Viking Global Investors LP | CT | T | P.d | 9,900 | 19.35 | 0 | 512 | 8 | 7,151 | I | |||||||||||||||
5/11/23 17:50 | 5/9/23 | FDMT | 4D Molecular Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Viking Global Investors LP | CT | T | P | 13,600 | 16.00 | 0 | 850 | 22 | 4,788 | I | |||||||||||||||
11/4/22 18:17 | 11/2/22 | FLAC | Frazier Lifesciences Acquisition Corp | E9 | Financ | AcqCo | Blank Checks | Viking Global Investors LP | CT | T | P | 8,538 | 10.08 | 0 | 847 | 232 | 1,212 | I | |||||||||||||||
10/12/22 16:39 | 10/7/22 | INBX | Inhibrx, Inc. | CA | Health | BioPrd | Biological Products, (No Diag | Viking Global Investors LP | CT | T | P | 40,000 | 30.00 | 0 | 1,333 | 46 | 4,212 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |